

Gilead and Kite Pipeline.



Active and planned clinical trials

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.

Our scientific focus areas target:



Oncology

| RESEARCH AREA | MOLECULE(S) | PHASE 1 | PHASE 2 | PHASE 3 |
|----------------------------|---|--|-------------|--------------------------|
| HEMATOLOGICAL MALIGNANCIES | 1L high-risk LBCL (ZUMA-23) | axicabtagene ciloleucl | NCT05605899 | |
| | R/R DLBCL | KITE-197 (next-gen CD19 CAR-T) | NCT06079164 | |
| | R/R DLBCL | KITE-363 (CD19/20 bicistronic) | NCT04989803 | |
| | R/R DLBCL | KITE-753 (CD19/20 bicistronic) | NCT04989803 | |
| | 2L+ high-risk FL (ZUMA-22) | axicabtagene ciloleucl | NCT05371093 | |
| | R/R Pediatric ALL/NHL (ZUMA-4) | brexucabtagene autoleucl | NCT02625480 | |
| | R/R MM (iMMagine-3) ^a | anitocabtagene autoleucl | NCT06413498 | |
| | R/R MM (iMMagine-1) ^a | anitocabtagene autoleucl | NCT05396885 | |
| | R/R MM (Phase 1) ^a | anitocabtagene autoleucl | NCT04155749 | |
| BREAST | 1L mTNBC, PD-L1- (ASCENT-03) | sacituzumab govitecan (SG) | NCT05382299 | Primary readout complete |
| | 1L mTNBC, PD-L1+ (ASCENT-04) ^b | sacituzumab govitecan + pembro | NCT05382286 | Primary readout complete |
| | Adjuvant TNBC (ASCENT-05) ^c | sacituzumab govitecan + pembro | NCT05633654 | |
| | HR+/HER2- chemo-naïve mBC (ASCENT-07) | sacituzumab govitecan | NCT05840211 | |
| THORACIC | 1L mNSCLC, PD-L1 TPS \geq 50% (EVOKE-03) ^b | sacituzumab govitecan + pembro | NCT05609968 | |
| | 2L ES-SCLC (EVOKE-SCLC-04) | sacituzumab govitecan | NCT05502237 | |
| | 1L mNSCLC, regardless of PD-L1 expression status (STAR-12) ^d | domvanalimab + zimberelimab + chemo | NCT05186974 | |
| | 1L mNSCLC (EVOKE-02) ^b | sacituzumab govitecan + pembro \pm chemo | NCT04262856 | |
| | Stage 2-3 resectable NSCLC, 1-2L mNSCLC (VELOCITY-Lung) ^{d,e} | zim \pm dom \pm etruma \pm chemo/SG combinations | NCT05633667 | |
| | 1L/2L+ mNSCLC (EDGE-Lung) ^f | zim \pm dom \pm quemli \pm chemo combinations | NCT06801834 | |
| | 1L r/m HNSCC, regardless of PD-L1 expression status (VELOCITY-HNSCC) ^g | zimberelimab + chemotherapy \pm domvanalimab | NCT06727565 | |
| GU | 1L/2L+ mUC (TROPHY U-01, multicohort) | sacituzumab govitecan + combinations | NCT03547973 | |
| GYN | 2L+ mEC (ASCENT-GYN-01) ^f | sacituzumab govitecan | NCT06486441 | |
| OTHER SOLID TUMORS | Solid tumors (EVER-132-003) | sacituzumab govitecan | NCT05119907 | |
| | Solid tumor basket study (TROPiCS-03) ^h | sacituzumab govitecan | NCT03964727 | |
| | Solid tumors | denikitug (CCR8) \pm zim | NCT05007782 | |
| | Solid tumors | GS-4528 (IL-2 variant) \pm zim | NCT05840224 | |
| | Solid tumors | GS-0201 (PARP1) \pm SG | NCT06167317 | |
| | Solid tumors | GS-2121 (undisclosed MoA) \pm zim | NCT06532565 | |
| | Solid tumors ⁱ | GS-0321 (IL18BP) \pm zim | NCT06759649 | |
| | Solid tumors | GS-5319 (undisclosed MoA) | NCT07128303 | |
| | Solid tumors ^j | XTX301 (IL-12) | NCT05684965 | |
| | Glioblastoma ^j | EGFR IL13Ra2 CAR-T | NCT05168423 | |
| | Neuroblastoma ^k | GPC2 CAR-T | NCT05650749 | |
| | Hepatocellular carcinoma | GPC3 Armored CAR-T | Planned | |

Non-oncology

| | | | |
|----|----------------------|--------------------------------|-------------|
| AD | Multiple indications | KITE-363 (CD19/20 bicistronic) | Preclinical |
|----|----------------------|--------------------------------|-------------|

Optionable Partner Programs^l



Targets

| | | | | | | | | | | | | | | | | | | | |
|---------|--------|-----------------|-----------|--------------------|---------------------|---------------------|---------|--------------|--------|------|-------|--------------------|------------|--------------------|-------------------------------------|--------|-----------|-----------------|---------|
| GS-0201 | SG | GS-5319 | Anito-cel | Axi-cel, Brexu-cel | KITE-197 | KITE-363, KITE-753 | GS-9911 | GS-4528 | XTX301 | Zim | Dom | EGFR IL13Ra2 CAR-T | GPC2 CAR-T | GPC3 Armored CAR-T | Etruma | Quemli | Denikitug | GS-2121 | GS-0321 |
| PARP1 | Trop-2 | undisclosed MOA | BCMA | CD19 | CD19 Next-gen CAR-T | CD19/20 bicistronic | DGKa | IL-2 variant | IL-12 | PD-1 | TIGIT | EGFR IL13Ra2 | GPC2 | GPC3 | A _{2A} R/A _{2B} R | CD73 | CCR8 | undisclosed MoA | IL18BP |

^aIn collaboration with Arcellx, Inc. ^bIn collaboration with Merck Sharp & Dohme. ^cIn collaboration with Alliance Foundation Trials, LLC and National Surgical Adjuvant Breast and Bowel Project Foundation, Inc. ^dIn collaboration with Arcus Biosciences. ^eGilead has returned its license to etrumadenant to Arcus. ^fIn collaboration with the Gynecologic Oncology Group (GOG) Foundation, the European Network of Gynaecological Oncological Trial Groups (ENGOT) and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT). ^gTROPiCS-03: mNSCLC, mSCLC, mHNSCC, mEC. ^hOperationalized by Compugen. Also referred to as COM503. ⁱOperationalized by Xilio Development, Inc. ^jIn collaboration with University of Pennsylvania. ^kIn collaboration with Children's Hospital of Philadelphia. ^lOptionable Partner Programs: Selected programs listed are optionable partner programs. Gilead has not opted into these programs unless otherwise noted.

1L, first line; 2L, second line; A_{2A}R/A_{2B}R, adenosine 2A receptor/adenosine 2B receptor; AD, autoimmune diseases; ALL, acute lymphoblastic leukemia; BC, breast cancer; BCMA, B-cell maturation antigen; CAPOX, capecitabine + oxaliplatin; CAR, chimeric antigen receptor; CCR8, chemokine receptor 8; CD19/20, cluster of differentiation 19/20; Chemo, chemotherapy; DLBCL, diffuse large B-cell lymphoma; dom, domvanalimab; EC, endometrial cancer; EGFR, epidermal growth factor receptor; ES-SCLC, extensive-stage small cell lung cancer; etruma, etrumadenant; FL, follicular lymphoma; FOLFOX, FOLinic acid, Fluorouracil and OXaliplatin; gem/nab-pac, gemcitabine/ nab-paclitaxel; GI, gastrointestinal; GPC2/3, glypican 2/3; GU, genitourinary; GYN, gynecological; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; HR, hormone receptor; IL-2/12, interleukin-2/12; IL13Ra2, interleukin-13 receptor subunit alpha 2; IL18P, interleukin-18 binding protein; LBCL, large B-cell lymphoma; m, metastatic; MM, multiple myeloma; MoA, mechanism of action; NCT, national clinical trial; NHL, non-Hodgkin lymphoma; nivo, nivolumab; NSCLC, non-small cell lung cancer; PARP1, poly adenosine diphosphate (ADP) ribose polymerase 1; PD-(L)1, programmed cell death (ligand) 1; pembro, pembrolizumab; quemli, quemliclustat; r/m, recurrent/metastatic; R/R, relapsed/refractory; SCLC, small cell lung cancer; SG, sacituzumab govitecan; TIGIT, T cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains; TNBC, triple-negative breast cancer; TPS, tumour proportion score; Trop-2, trophoblast cell surface antigen 2; UC, urothelial cancer; zim, zimberelimab.